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Abstract
Variations in the gene for the nucleotide-binding oligomerisation domain (NOD) 2 have been associated with Crohn’s
disease but not multiple sclerosis (MS). Here we investigate the effect of three polymorphisms in the NOD2 gene (rs5743277,
rs2066842 and rs5743291) on cytokine production and CD4+ T cell proliferation elicited by human myelin basic protein
(MBP) in blood mononuclear cell (MNC) cultures from 29 patients with MS. No polymorphism was observed at rs5743277.
No associations with the rs2066842 polymorphism were found. Concerning rs5743291, none were homozygous for the
minor allele. Seven of 29 (24%) patients were heterozygous, and five of these (71%) exhibited increased MBP-induced CD4+
T cell proliferation versus four of 22 (18%), who were homozygous for the major allele (p,0.04). Interleukin (IL)-5 was
induced by MBP in MNC from the same five carriers versus two (9%) homozygotes (p,0.004); four carriers (57%) versus
three non-carriers (14%) exhibited IL-17 responses to MBP (p,0.04). By contrast, we found no association between the
polymorphisms investigated and interferon-gamma-, tumor necrosis factor-alpha-, IL-2, -4- or IL-10 responses to MBP. These
results indicate that the rs5743291 polymorphism influences T helper (Th) cell 2- and Th17 cell responses in MNC from MS
patients.
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Introduction
Pattern recognition receptors (PRRs) recognizing ‘‘non-host’’
molecular patterns play an essential role in recognition of
microbial pathogens by cells of the innate immune system [1].
The nucleotide-binding oligomerization domain (NOD)-like
receptor NOD2 is an intracellular PRR recognizing the
bacterial peptidoglycan derivative muramyl dipeptide (MDP),
reviewed in Mathews et. al. [2]. NOD2 comprises two N-
terminal caspase recruitment domains (CARD), a central
nucleotide binding domain, referred to as NACHT, and a C-
terminal leucine-rich repeat (LRR) domain [3]. The effector of
NOD2 is the LRR domain, which upon activation by MDP
induces production of proinflammatory cytokines by signaling
through nuclear factor kappa B (NF-kappaB), reviewed in
Takeuchi et. al. [4].
Mutations in NOD2 gene confer susceptibility to several
chronic inflammatory disorders, including Crohn’s disease and
Blau syndrome [5,6,7]. Thirty non-conservative mutations
associated with Crohn’s disease have been identified within
the NOD2 gene, but only three are common, namely those
leading to the Arg702Trp and Gly908Arg substitutions, and a
frame shift mutation (3020insCR1007fs) resulting in a
truncated version of NOD2. These three variants are all
situated in the LRR domain of NOD2, mutations in which
result in failure to activate the NF-kappaB signal transduction
pathway upon binding of NOD2 ligands [3,5,6,7,8]. The
3020insC mutation lowers interleukin (IL)-10 syntheses by
inhibiting the activity of heterogeneous nuclear ribonucleopro-
tein A1 [9,10,11]. Mutations in the NACHT domain, on the
other hand, result in elevated MDP-induced up-regulation of
N F - k a p p a B[ 1 2 ] .T h et h r e em u t a t i o n si nt h eL R Rm e n t i o n e d
above do not appear to confer susceptibility to multiple
sclerosis (MS) [13].
Stimulation of human dendritic cells with MDP has been shown
to enhance NOD2-mediated production of IL-23, IL-1 by the
dendritic cells and, in turn, promote IL-17 production by memory
Th17 cells [14]. IL-17 has been shown to be involved in chronic
inflammatory diseases, including MS and Crohn’s disease
[15,16,17,18,19,20,21].
We recently demonstrated a close association between active
cerebral lesions in multiple sclerosis (MS) and CD4+ Tc e l l
proliferation and mononuclear cell (MNC) production of IL-17
and IL-5 induced by myelin basic protein (MBP) ex vivo [18].
Proliferative CD4+ T cell responses and production of IL-17,
IFN-c, and IL-5 and IL-4 were only seen in a subgroup of high-
responder patients and not in healthy controls. In view of the
reported influence of NOD2-signaling on IL-17 production, we
have here examined whether certain single nucleotide polymor-
phisms (SNPs) in the NOD2 gene were characteristic for high-
responder patients, and demonstrate that a G.A substitution in
exon 9 of the NOD2 gene is associated with MBP-induced CD4+
T cell proliferation, IL-5 production, and IL-17 production, but
not with increased Th1 -responses.
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Ethics Statements
The study was approved by the Scientific Ethics Committe ´e of
Copenhagen and Frederiksberg, and prior to blood draw, all
participating subjects gave their verbal and written informed
consent.
Subjects
The study included 29 patients with MS, 20 women and
nine men, median age: 34 yrs, range: 23-44 yrs (Table 1), and
27 of these patients were diagnosed with relapsing-remitting
MS (RRMS) and two with clinically isolated MS syndrome. All
patients were untreated at the time of inclusion. None had
been treated with immunosuppressive drugs, and none had
been treated with glucocorticoids within four weeks of study
entry.
Cells and serum
Blood was collected in lithium-heparin tubes and dry Vacutai-
ner tubes (BD Bioscience, Brøndby, Denmark). MNCs were
isolated from the former by density centrifugation on Ficoll-
Hypaque, LymphoprepH (Nycomed, Oslo, Norway), and serum
was isolated from the latter tubes. The MNCs were labeled with
2 mM 5,6-carboxyfluorescein-diacetate-succinimidyl-ester (CFSE;
Molecular Probes/Invitrogen, Taastrup, Denmark) and cultured
in 96-well Nunclon
TM flat-bottomed MicroWell
TM plates
(Thermo Fischer Scientific, Slangerup, Denmark).
Stimulation of MNCs with MBP
Cultures of the labeled MNCs (5610
5 cells per well) were
grown in RPMI 1640 (Biological Industries, Kibbutz Beit
H a e m e k ,I s r a e l ) ,c o n t a i n i n g5 0 mg/mL Gentamycin (Gibco/
Invitrogen), 2 mM glutamine (Gibco/Invitrogen), and 30% (v/v)
serum to a final volume of 150 mL per well. The cells were grown
Table 1. Patient characteristics.
Patient # Gender Age Diagnosis
1
MBP-induced CD4+
T cell proliferation
2 NOD2 polymorphisms
rs2066842 rs5743277 rs5743291
1 M 23 RRMS - C/C C/C G/G
2 M 24 RRMS - T/T C/C G/G
3 F 25 RRMS + C/T C/C G/A
4 F 35 RRMS + C/C C/C G/G
5 F 25 CIS - C/T C/C G/G
6 F 28 RRMS + C/C C/C G/A
7 F 35 RRMS + C/T C/C G/A
8 F 28 RRMS - C/T C/C G/A
9 M 29 RRMS + C/T C/C G/A
10 F 29 RRMS + C/C C/C G/G
11 M 30 RRMS - C/T C/C G/G
12 F 29 RRMS - C/C C/C G/G
13 M 32 RRMS - C/C C/C G/G
14 F 33 RRMS - C/T C/C G/G
15 M 35 RRMS - C/T C/C G/G
16 F 34 RRMS - C/T C/C G/G
17 F 36 RRMS - C/C C/C G/G
18 F 37 RRMS - C/T C/C G/G
19 F 38 RRMS + T/T C/C G/G
20 F 38 RRMS - C/C C/C G/G
21 M 39 RRMS - C/C C/C G/G
22 F 30 RRMS + C/T C/C G/G
23 M 39 RRMS - C/T C/C G/G
24 F 39 CIS - C/C C/C G/A
25 M 41 RRMS - C/T C/C G/G
26 F 27 RRMS + C/C C/C G/A
27 F 42 RRMS - C/C C/C G/G
28 F 42 RRMS - C/C C/C G/G
29 F 44 RRMS - C/T C/C G/G
Minor alleles are marked in bold.
1RRMS: relapsing-remitting MS, CIS: clinically isolated syndrome.
2Positivity was defined as more than 1% dividing CD4+ T cells after allowance for background proliferation.
doi:10.1371/journal.pone.0020253.t001
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presence of purified human MBP (HyTest, Turku, Finland) at a
concentration of 30 mg/mL. Culture supernatant, 85 mL, was
removed on days one and seven for assessment of cytokine
contents, and the cultures were supplemented with 100 mLo f
RPMI at these time points.
The MBP preparation used was tested by mass spectrometry
and found to be .95% pure, and the major contaminant being
hemoglobin. No traces of the NOD2 ligand MDP were found, and
all the measured MBP-induced responses were abrogated by
boiling the MBP preparation showing that the responses observed
were not induced by contaminating LPS [22].
Measurement of cytokines
The content of the cytokines IL-4, IL-5, IL-10, IL-2, tumor-
necrosis factor (TNF)-alpha and interferon (IFN)-gamma in the
culture supernatants and patient sera were measured by flow
cytometry using the cytometric bead array (CBA) Th1/Th2 kit
and the corresponding software (CellQuest, BD Bioscience)
according to the manufacturer’s protocol, except that three-fold
dilutions of all reagents were used. IL-17 was measured with an
IL-17 singleplex kit (Invitrogen) using a Luminex 100 IS (Luminex
corp., Austin, Texas, USA). Data analyses were carried out with
StarStation version 2.0 software (Applied Cytometry Systems,
Sheffield, UK).
A positive cytokine response was defined as $5 pg/ml after
subtraction of the production in the absence of stimulating antigen.
Measurement of proliferation
Measurement of CD4+ T cell proliferation was carried out as in
Nielsen et. al. [23] In brief, cell divisions were tracked on the basis
of the CFSE-content, which is halved upon each cell division. Cells
with a fluorescence intensity of less than one half of the intensity of
undivided cells were considered proliferating cells. T helper (Th)
cells were identified as cells within a morphological (forward-/side
scatter) lymphocyte gate staining with PerCP-anti-CD4 antibodies
(BD Bioscience). Proliferation was measured at day 10 using a
FACScalibur flow cytometer (BD Bioscience). Responders to MBP
were defined as individuals with $1% divided CD4+ T cells after
allowance for the background proliferation occurring in the
absence of stimulating antigen.
Genotyping
Genotyping was performed using in-house bead-based
multiplex single nucleotide polymorphism (SNP) assays as
described elsewhere [24]. Briefly, allele-specific primers were
labeled in an allele-specific primer extension (ASPE) reaction,
using polymerase chain reaction- a m p l i f i e dS N P - s i t e sa st h e i r
target sequences. The labeled ASPE-primers were subsequently
hybridized to MicroPlex-xTAG beadsets for detection and
counting on the Luminex 100 IS platform. Three SNPs were
investigated in NOD2: rs2066842, rs5743277, and rs5743291
(Table 2).
Statistics
Prism 4 (GraphPad, San Diego, CA, USA) was employed for
statistical analysis. The Mann-Whitney U-test was used for
comparison of unpaired data, and the Kruskall-Wallis test was
used for testing equality of medians among groups. Spearman’s
rank correlation coefficient was used to determine whether two
sets of data were associated. The Fisher’s exact test was used to
calculate the distribution of dichotomic data (present versus not
present). P-values ,0.05 were considered significant.
Results
NOD2 polymorphisms
We examined 29 MS patients for three most common
polymorphisms in the NOD2 gene: rs2066842 (Pro268Ser),
rs5743277 (Arg703Cys), and rs5743291 (Val955Ile). Proline 268
is situated in the NACHT domain, whereas arginine 703 and
valine 955 are situated in the LRR domain. No carriers of the
minor allele of the rs5743277 polymorphism were found among
the included patients (Table 1). Fourteen patients were heterozy-
gous carriers (C/T) of the rs2066842 polymorphism and two were
homozygous carriers of the T-allele. Seven patients were
heterozygous (G/A) for the A-allele of the rs5743291 polymor-
phism, while none were homozygous.
Influence of rs5743291 and rs2066842 polymorphisms on
MBP-induced cytokine responses
We examined whether polymorphisms in NOD2 influenced
MBP-induced cytokine responses by MNCs isolated from 29 MS
patients. After 24 hours of incubation with antigen, a significant
production of TNF-alpha occurred in all MNC cultures tested, IL-
4 production was observed in cultures from nine patients (Table 2),
IFN-gamma production was observed in 24 (not shown), whereas
cultures from only three patients produced IL-2 (not shown), and
none produced IL-5 or IL-17.
MBP-induced IL-10 production was found in cultures from all
patients but one (Table 2).
As shown in Figure 1A the IL-10 production was non-
significantly reduced in patients carrying the minor allele of
rs5743291 alone, rs2066842 alone or both (by 49%, 46% and
37%, respectively).
After seven days of stimulation with MBP, production of IL-5
had taken place in seven of 29 patient cultures (Table 2 and
Fig. 1B), IFN-gamma in 14, IL-2 in eight, IL-17 in seven (Table 2),
and IL-4 in four cultures (not shown).
As shown in Figure 1B, the MBP-induced production of IL-5 was
significantly associated with the NOD2 genotype (Kruskall-Wallis test:
Table 2. Influence of the rs5743291 polymorphism on MBP-
induced CD4+ T cell responses.
rs5743291
G/G
1
(n=22)
G/A
(n=7) Test results
2
Response to MBP Yes No Yes No G/G vs. G/A
CD4+ Tc e l l
proliferation
3
41 8 5 2 P ,0.02
IFN-gamma
production
4
91 3 5 2 P ,0.22
IL-2 production
4 51 7 3 4 P ,0.36
IL-4 production
5 51 7 3 4 P ,0.36
IL-5 production
4 22 0 5 2 P ,0.004
IL-17 production
4 31 9 4 3 P ,0.04
TNF-alpha was produced in all cases and IL-10 in 28 out of 29 cases. These
cytokines were not included in the table.
1G-allele = major frequency allele.
2Fisher’s exact test.
3CD4+ T cell proliferation measured after 10 days incubation.
4Cytokines measured in cell cultures supernatants after seven days stimulation
with MBP.
5Cytokine measured in cell cultures supernatants after one day of stimulation
with MBP.
doi:10.1371/journal.pone.0020253.t002
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minor alleles of the rs5743291 polymorphism displayed significantly
higher contents of IL-5 (median 70 pg/ml) after stimulation with
MBP than cultures from patients homozygous for the G-allele, in
which the IL-5 content was, on median, undetectable (p,0.02;
Fig. 1B). Accordingly, carriers of the G.A substitution in rs5743291
morefrequently responded to MBP with IL-5 production than (G/G)
homozygous patients (p,0.004; Table 2).
The MBP-elicited production of IL-17 was also associated with
the NOD2 genotypes (Fig. 1C), the median content of IL-17 in
MNC cultures derived from patients carrying the minor allele of
both polymorphisms being 15 pg/ml and undetectable in patients
carrying one or no minor alleles of rs5743291 (Kruskall-Wallis test:
p,0.09). IL-17 responses to MBP were thus observed in MNC
cultures from four out of the seven patients carrying the minor A-
allele of rs5743291 versus three out of 19 cultures from patients
who were homozygous for the major allele (p,0.04; Table 2).
Carriers of the minor allele of rs2066842 alone did not show
increased IL-5 responses or IL-17 responses.
We observed no association between either of the two
polymorphisms and the production of IFN-gamma, IL-2, or IL-
4 (Table 2; not shown for rs2066842).
Influence of rs5743291 and rs2066842 polymorphisms on
MBP-induced CD4+ T cell proliferation
After 10 days of incubation with MBP, the proliferation of
CD4+ T cells was assessed in the MS patient-derived cultures. As
shown in Table 2, heterozygosity (G/A) in rs5743291 was
associated with more frequent CD4+ T cell proliferative responses
to MBP (p,0.02). Thus, five out of nine patients showing MBP-
induced CD4+ T cell proliferation were heterozygous for this
polymorphism, and three of them also carried the minor allele of
rs2066842 (Fig. 1D). The five patients with CD4+ T cell
Figure 1. Influence of NOD2-polymorphisms on MBP-induced Th cell responses. CFSE-labeled mononuclear cells from twenty-nine
patients were incubated for 10 days in medium containing (30% v/v) autologous serum and 30 mg/ml human MBP. (A) The contents of IL-10 in the
culture supernatants were assessed after one day of incubation, and the contents of (B) IL-5 and (C) IL-17 were quantified after seven days. After 10
days of incubation, division of CD4+ T cells (D) was tracked by flow cytometry as cells having undergone more than one division. The data were
grouped according to the patients’ NOD2-polymorphisms: Nine were homozygous wildtypes for both rs2066842 and rs5743291 (WT; open circles), 13
carried the minor allele of rs2066842 only (light shaded circles), three carried the minor allele of rs5743291 (dark shaded circles), and four carried the
minor allele of both polymorphisms (closed circles). Net values, after subtractions of background activities, are shown. Horizontal lines show the
medians, and P-values were calculated using the Mann-Whitney U-test.
doi:10.1371/journal.pone.0020253.g001
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production (Fig. 2A), but only three of them responded with IL-17
production (Fig. 2B). The remaining four responders were equally
distributed between patients carrying the minor allele of
rs2066842 alone and patients homozygous for the major allele.
As reported previously, 14 of the patients were followed for six
months after initiation of IFN-beta therapy [25]. During this
period, an additional four patients exhibited MBP-induced CD4+
T cell proliferation, including the two heterozygous patients
without pretreatment response. Thus all seven heterozygous (G/A)
patients responded to MBP with CD4+ T cell proliferation at one
or more time points within the observation period versus only six
patients who were homozygous for the major allele (p,0.002; not
shown).
Circulating cytokine levels
To test whether the exaggerated MBP-induced cytokine
responses in patients carrying the minor allele of rs5743291 were
reflected by increased levels of circulating cytokines in vivo,w e
measured IL-2, IL-4, IL-5, IL-10, IL-17, TNF-alpha, and IFN-
gamma in sera from 27 of the patients included in the study; seven
who carried the minor allele of the rs5743291 polymorphism, and
twenty who were homozygous for the major allele. IFN-gamma
(5–12 pg/ml) was found in three sera; from a patient who were
heterozygous for the minor alleles of both rs5743291 and
rs2066842 and from two patients who carried neither of the
minor alleles (NS). A fourth patient, heterozygous for both minor
alleles, had detectable IL-10 levels (10 pg/ml; data not shown). No
other circulating cytokines were detected (data not shown). None
of the patients displayed spontaneous CD4+ T cell proliferation.
Discussion
Mutations in NOD2 have been associated with chronic
inflammatory disorders such as Crohn’s disease and Blau
syndrome. Following our previous findings that a MNCs from a
subgroup of MS patients respond to challenge with MBP ex vivo
with CD4+ T-cell proliferation and production of IL-17, IFN-c,
IL-5 and IL-4 [18], we have here examined whether these
responses are associated with the three most common NOD2
mutations. The influence of rs5743277 could not be investigated,
since all patients examined were homozygous for the major allele.
The rs2066842 polymorphism did not significantly influence the
cellular responses to MBP, while patients carrying the minor allele
of rs5743291, resulting in a substitution of Valine955 with
isoleucine in the LRR domain, displayed excessive T cell
responses, as illustrated by enhanced CD4+ T cell proliferation.
We were unable to demonstrate associations between the
polymorphisms and MBP-induced Th1-responses but did observe
enhanced IL-5 and, notably, IL-17 responses in patients who were
heterozygous for the G.A substitution in rs5743291. Concomi-
tantly, these patients displayed a non-significant reduction (by 37–
49%) of the IL-10 production, in keeping with previous findings
that mutations in the LRR domain of NOD2 are associated with
reduced expression of this cytokine [10]. While IL-10 is known to
play a protective role in MS [26], we have previously observed
that the level of MBP-induced IL-5 correlated positively with
disease activity [18], and that T cells from secondary progressive
MS patients have a higher expression of IL-5 than those of RRMS
patients [27]. On the other hand, IL-5 is upregulated during
glatiramer acetate therapy and does not appear to increase during
relapses like another Th2 cytokine, IL-13 [28,29]. It is possible
that Th2 cells play different roles at different stages of MS.
The role of Th17 cell in the pathogenesis of MS has been
intensively investigated during recent years. For example,
inflammation in the brain parenchyma apparently occurs when
Th17 cells outnumber Th1 cells, resulting in elevated IL-17
expression, and IL-17 production correlates with disease activity
[18,30,31]. Thus, the exaggerated IL-17 response to MBP in four
out of seven patients carrying the minor allele of rs5743291 is
likely to have detrimental consequences.
The exaggerated production of IL-5 and IL-17 in cultures
derived from MS patients heterozygous for the G.A substitution
in rs5743291 were not reflected by detectable levels of these
cytokines in the circulation.
It was not possible to include a group of healthy controls to
examine the relationship between NOD2 polymorphism and MBP-
induced CD4+ T-cell proliferation or production of IL-17, IFN-c,
IL-5 and IL-4, since MBP induces these responses in patient-
derived cultures exclusively [18].
Figure 2. Correlation between MBP-induced Th-cell proliferation and production of IL-17 and IL-5. The MBP-induced IL-5 responses (A)
and IL-17 responses (B) were compared with the CD4+ T cell proliferation of seven multiple sclerosis patients who were heterozygous for the minor
A-allele of rs5743291. Closed circles (n=4) represent patients who also carried the minor T-allele of the rs2066842 polymorphism. Spearman’s rank
correlation coefficient was used to determine association between data sets.
doi:10.1371/journal.pone.0020253.g002
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time that T cell proliferative responses and IL-5/IL-17 responses
to a myelin self-antigen are linked with NOD2 polymorphism. It is
known that mutations in LRR of the encoded protein NOD2 are
associated with reduced production of IL-10, which plays a
protective (antiinflammatory) role in MS [10,26].
Our study was hampered by the low number of MS patients
included and the lack of patients homozygous for the minor alleles
of the polymorphisms examined (none for rs5743277 and
rs5743291, and only two for rs2066842). Therefore, the results
can only be regarded as hypothesis-generating, and studies of
larger cohorts or more homozygous patients are needed to certify
associations between the polymorphisms and Th1- and IL-10
responses to MBP or other MS-associated self-antigens. Moreover,
the mechanisms behind the apparent effect of NOD2 polymor-
phism and IL-5/IL-17 production need to be elucidated.
In summary, our data indicate that MNCs derived from MS
patients, who are heterozygous for a G.A substitution in exon 9
of the NOD2 gene, display enhanced CD4+ T cell proliferation
and production of IL-5 and IL-17 in response to challenge with the
myelin self-antigen MBP. Studies in larger cohorts of patient are
needed to confirm this hypothesis. While the enhanced IL-17
production may have pathophysiological implications, the role of
IL-5 in MS needs further investigation.
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